

Recombinant Human soluble Tumor Necrosis Factor-Related Apoptosis-inducing Ligand Receptor-2/TNFRSF10B

#R00095

Size: 10 µg/100 µg/500 µg

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.



Warning: This product is intended for scientific research only. It is not to be used for medical or diagnostic procedures in humans or animals, nor as a food, cosmetic, or household product.

Background

Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells. TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients.

AA Sequence

ESALITQQDLAPQQRAAPQQKRSSPSEGLCPPGHHI
SEDGRDCISCKYGGDYSTHWNDLLFCLRCTRCDSG
EVELSPCTTTRNTVCQCEEGTFREEDSPEMCRKCRT
GCPRGMVKVGDCPTWSDIECVHKES

Reconstitution

We recommend that this vial be briefly centrifuged prior

to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Product Specification

Synonyms	soluble TRAIL Receptor-2, DR5, TNFRSF10B, KILER, TRICK2A, TRICKB
Accession	O14763
GeneID	8795
Species	Human
Source	Escherichia coli.
Molecular Weight	Approximately 14.8 kDa, a single non-glycosylated polypeptide chain containing 132 amino acids.
Purity	> 97 % by SDS-PAGE and HPLC analyses.
Biological Activity	Fully biologically active when compared to standard. rHusTRAIL-R2 reduced the production of LPS-induced TNF by its ability to neutralize

endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/mL) but in the presence of rHusTRAIL-R2, TRAIL-induced TNF is suppressed.

Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.

Endotoxin Less than 1 EU/µg of rHusTRAIL-R2 as determined by LAL method.
